Generic placeholder image

Current Bioinformatics

Editor-in-Chief

ISSN (Print): 1574-8936
ISSN (Online): 2212-392X

Research Article

Identification of Glioma Specific Genes as Diagnostic and Prognostic Markers for Glioma

Author(s): Ming Tu, Ling Ye, ShaoBo Hu, Wei Wang, Penglei Zhu, XiangHe Lu and WeiMing Zheng*

Volume 16, Issue 1, 2021

Published on: 24 April, 2020

Page: [120 - 129] Pages: 10

DOI: 10.2174/1574893615999200424090954

Price: $65

Abstract

Background: Malignant gliomas are the most prevalent malignancy of the brain. However, there was still lack of sensitive and accurate biomarkers for gliomas.

Objective: To explore the mechanisms underlying glioma progression and identify novel diagnostic and prognostic markers for glioma.

Methods: By analyzing TCGA dataset, whole-genome genes expression levels were evaluated in 19 different types of human cancers. A protein-protein interacting network was constructed to reveal the potential roles of these glioma special genes. KEGG and GO analysis revealed the potential effect of these genes.

Results: We identified 698 gliomas specially expressed genes by analyzing TCGA dataset. A protein-protein interacting network was constructed to reveal the potential roles of these glioma special genes. KEGG and GO analysis showed gliomas specially expressed genes were involved in regulating neuroactive ligand-receptor interaction, retrograde endocannabinoid signaling, Glutamatergic synapse, chemical synaptic transmission, nervous system development, central nervous system development, and learning. Of note, GRIA1, GNAO1, GRIN1, CACNA1A, CAMK2A, and SYP were identified to be down-regulated and associated with poor prognosis in gliomas.

Conclusion: GRIA1, GNAO1, GRIN1, CACNA1A, CAMK2A, and SYP were identified to be down-regulated and associated with poor prognosis in gliomas. We thought this study will provide novel biomarkers for gliomas.

Keywords: Glioma, glioma specific gene, biomarker, prediction, protein-protein interaction, prognosis.

Graphical Abstract

[1]
Dolecek TA, Propp JM, Stroup NE, Kruchko C. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro-oncol 2012; 14(Suppl. 5): v1-v49.
[http://dx.doi.org/10.1093/neuonc/nos218] [PMID: 23095881]
[2]
Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro-oncol 2014; 16(Suppl. 4): iv1-iv63.
[http://dx.doi.org/10.1093/neuonc/nou223] [PMID: 25304271]
[3]
Beal K, Abrey LE, Gutin PH. Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: analysis of single-agent and combined modality approaches. Radiat Oncol 2011; 6: 2.
[http://dx.doi.org/10.1186/1748-717X-6-2] [PMID: 21214925]
[4]
Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007; 114(2): 97-109.
[http://dx.doi.org/10.1007/s00401-007-0243-4] [PMID: 17618441]
[5]
Quick A, Patel D, Hadziahmetovic M, Chakravarti A, Mehta M. Current therapeutic paradigms in glioblastoma. Rev Recent Clin Trials 2010; 5(1): 14-27.
[http://dx.doi.org/10.2174/157488710790820544] [PMID: 20205684]
[6]
Perry J, Okamoto M, Guiou M, Shirai K, Errett A, Chakravarti A. Novel therapies in glioblastoma. Neurol Res Int 2012.2012428565
[http://dx.doi.org/10.1155/2012/428565] [PMID: 22530121]
[7]
Reon BJ, Anaya J, Zhang Y, et al. Expression of lncRNAs in Low-Grade Gliomas and Glioblastoma Multiforme: An In Silico Analysis. PLoS Med 2016; 13(12)e1002192
[http://dx.doi.org/10.1371/journal.pmed.1002192] [PMID: 27923049]
[8]
Yang L, Li C, Liang F, Fan Y, Zhang S. MiRNA-155 promotes proliferation by targeting caudal-type homeobox 1 (CDX1) in glioma cells. Biomed Pharmacother 2017; 95: 1759-64.
[http://dx.doi.org/10.1016/j.biopha.2017.08.088] [PMID: 28962081]
[9]
Xue L, Wang Y, Yue S, Zhang J. The expression of miRNA-221 and miRNA-222 in gliomas patients and their prognosis. Neurol Sci 2017; 38(1): 67-73.
[http://dx.doi.org/10.1007/s10072-016-2710-y] [PMID: 27629767]
[10]
Tritz R, Mueller BM, Hickey MJ, et al. siRNA Down-regulation of the PATZ1 Gene in Human Glioma Cells Increases Their Sensitivity to Apoptotic Stimuli. Cancer Ther 2008; 6(B): 865-76.
[PMID: 19081762]
[11]
Schafer M, Tegeder I. NG2/CSPG4 and progranulin in the posttraumatic glial scar. Matrix Biol 2017.
[PMID: 29054751]
[12]
Tsidulko AY, Kazanskaya GM, Kostromskaya DV, et al. Prognostic relevance of NG2/CSPG4, CD44 and Ki-67 in patients with glioblastoma. Tumour Biol 2017; 39(9)1010428317724282
[http://dx.doi.org/10.1177/1010428317724282] [PMID: 28945172]
[13]
Luo G, Hu Y, Zhang Z, et al. Clinicopathologic significance and prognostic value of Ki-67 expression in patients with gastric cancer: a meta-analysis. Oncotarget 2017; 8(30): 50273-83.
[http://dx.doi.org/10.18632/oncotarget.17305] [PMID: 28488584]
[14]
Qiu X, Mei J, Yin J, Wang H, Wang J, Xie M. Correlation analysis between expression of PCNA, Ki-67 and COX-2 and X-ray features in mammography in breast cancer. Oncol Lett 2017; 14(3): 2912-8.
[http://dx.doi.org/10.3892/ol.2017.6516] [PMID: 28927045]
[15]
Matsuse M, Yabuta T, Saenko V, et al. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors. Sci Rep 2017; 7: 41752.
[http://dx.doi.org/10.1038/srep41752] [PMID: 28150740]
[16]
Wu D, Zhu X, Jimenez-Cowell K, et al. Identification of the GTPase-activating protein DEP domain containing 1B (DEPDC1B) as a transcriptional target of Pitx2. Exp Cell Res 2015; 333(1): 80-92.
[http://dx.doi.org/10.1016/j.yexcr.2015.02.008] [PMID: 25704760]
[17]
Dennis G Jr, Sherman BT, Hosack DA, et al. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol 2003; 4(5): 3.
[http://dx.doi.org/10.1186/gb-2003-4-5-p3] [PMID: 12734009]
[18]
Zhang YA, Zhou Y, Luo X, et al. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. EBioMedicine 2016; 13: 80-9.
[http://dx.doi.org/10.1016/j.ebiom.2016.10.040] [PMID: 27840009]
[19]
Li Z, Yan X, Sun Y, Yang X. Expression of ADP-ribosyltransferase 1 Is Associated with Poor Prognosis of Glioma Patients. Tohoku J Exp Med 2016; 239(4): 269-78.
[http://dx.doi.org/10.1620/tjem.239.269] [PMID: 27466078]
[20]
Shi H, Zhang S. Expression and prognostic role of orphan receptor GPR110 in glioma. Biochem Biophys Res Commun 2017; 491(2): 349-54.
[http://dx.doi.org/10.1016/j.bbrc.2017.07.097] [PMID: 28728843]
[21]
Zhang S, Zhao BS, Zhou A, et al. m6A Demethylase ALKBH5 Maintains Tumorigenicity of Glioblastoma Stem-like Cells by Sustaining FOXM1 Expression and Cell Proliferation Program. Cancer Cell 2017; 31(4): 591-606.e6.
[http://dx.doi.org/10.1016/j.ccell.2017.02.013] [PMID: 28344040]
[22]
Tang Y, Li M, Wang YL, et al. ART1 promotes starvation-induced autophagy: a possible protective role in the development of colon carcinoma. Am J Cancer Res 2015; 5(2): 498-513.
[PMID: 25973293]
[23]
Su X, Liu X, Ni L, et al. GFAP expression is regulated by Pax3 in brain glioma stem cells. Oncol Rep 2016; 36(3): 1277-84.
[http://dx.doi.org/10.3892/or.2016.4917] [PMID: 27432276]
[24]
Rajić V, Debeljak M, Goričar K, Jazbec J. Polymorphisms in GRIA1 gene are a risk factor for asparaginase hypersensitivity during the treatment of childhood acute lymphoblastic leukemia. Leuk Lymphoma 2015; 56(11): 3103-8.
[http://dx.doi.org/10.3109/10428194.2015.1020802] [PMID: 25697915]
[25]
Liu Z, Zhang J, Wu L, Liu J, Zhang M. Overexpression of GNAO1 correlates with poor prognosis in patients with gastric cancer and plays a role in gastric cancer cell proliferation and apoptosis. Int J Mol Med 2014; 33(3): 589-96.
[http://dx.doi.org/10.3892/ijmm.2013.1598] [PMID: 24366063]
[26]
Pei X, Zhang J, Wu L, et al. The down-regulation of GNAO1 and its promoting role in hepatocellular carcinoma. Biosci Rep 2013; 33(5): 33.
[http://dx.doi.org/10.1042/BSR20130001] [PMID: 23984917]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy